share_log

Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $8

Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $8

Craig-Hallum维持对Champions Oncology的买入评级,将目标价上调至8美元
Benzinga ·  12/13 00:23  · 评级/大行评级

Craig-Hallum analyst Matt Hewitt maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $6 to $8.

Craig-Hallum的分析师Matt Hewitt维持Champions Oncology(纳斯达克:CSBR)的买入评级,并将价格目标从$6提高至$8。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发